Slower heart rates for healthy hearts: time to redefine tachycardia?
Gopinathannair
Rakesh
R
Sullivan
Renee M
RM
Olshansky
Brian
B
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001262:Atenolol / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control; D004562:Electrocardiography; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D017379:Hypertrophy, Left Ventricular / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control; D015994:Incidence; D019808:Losartan / Q000627:therapeutic use; D012016:Reference Values; D018570:Risk Assessment; D012307:Risk Factors; D013610:Tachycardia / Q000503:physiopathology*; D013997:Time Factors; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001262:Atenolol; D019808:Losartan